Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
COMPARISON OF THE PHARMACOKINETICS OF LAMOTRIGINE IN PATIENTS WITH CHRONIC-RENAL-FAILURE AND HEALTHY-VOLUNTEERS
Autore:
WOOTTON R; SOULLAWTON J; ROLAN PE; SHEUNG CTCF; COOPER JDH; POSNER J;
Indirizzi:
INST OCCUPAT MED LTD,SKELTON HOUSE,MANCHESTER SCI PK,LLOYD ST N MANCHESTER M15 6SH LANCS ENGLAND WELLCOME RES LABS,DEPT CLIN PHARMACOL BECKENHAM BR3 3BS KENT ENGLAND WELLCOME RES LABS,DEPT BIOANAL & DRUG METAB BECKENHAM BR3 3BS KENT ENGLAND CLIN INNOVAT LTD KENILWORTH ENGLAND
Titolo Testata:
British journal of clinical pharmacology
fascicolo: 1, volume: 43, anno: 1997,
pagine: 23 - 27
SICI:
0306-5251(1997)43:1<23:COTPOL>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
POTENTIAL ANTIEPILEPTIC DRUG; EPILEPSY; ANTICONVULSANT; VALPROATE; BW430C;
Keywords:
LAMOTRIGINE; LAMOTRIGINE GLUCURONIDE; RENAL FAILURE; PHARMACOKINETICS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
19
Recensione:
Indirizzi per estratti:
Citazione:
R. Wootton et al., "COMPARISON OF THE PHARMACOKINETICS OF LAMOTRIGINE IN PATIENTS WITH CHRONIC-RENAL-FAILURE AND HEALTHY-VOLUNTEERS", British journal of clinical pharmacology, 43(1), 1997, pp. 23-27

Abstract

Aims The aim of this study was to compare the pharmacokinetics of theantiepileptic agent, lamotrigine, in patients with chronic renal failure and healthy volunteers. Methods Non-compartmental pharmacokineticsof a single oral dose (200 mg) of the anti-epileptic agent, lamotrigine, and its main metabolite, lamotrigine N-2-glucuronide, were determined for 10 patients with chronic renal failure of mean estimated creatinine clearance 18 mlmin(-1) and a control group of 11 healthy volunteers, matched for age and gender. Results For lamotrigine, there were no significant differences in C-max, f(max), AUC t(1/2,z), CL/F and amount excreted in urine although t(1/2,z) tended to be longer for the renal failure group with a mean (+/- s.d.) of 35.9 +/- 10.7 h vs 27.8 +/- 4.3 h for the control group. For the renal failure group, V-Z/F was 18% higher (95% Cl 1% to 39%) compared with controls and CLR was reduced to 61% (95% Cl 46% to 80%) of the control group value. For lamotrigine glucuronide, C-max was increased 4-fold (95% Cl 3.1 to 5.3) and AUC 7.8-fold (95% Cl 6.0 to 10.1) in the renal failure group compared with controls. CL(R) was approximately 9-fold lower and apparent t(1/2) was increased by 53% (95% Cl 27% to 84%). Concentrations of an N-2-methylated cardio-active metabolite, previously observed in dogs, were below the limit of detection (2 ng ml(-1)) of the ASTED/h.p.l.c. assay in the renal failure group as well as controls. Conclusions These results indicate that impaired renal function will have little effect on the plasma concentrations of lamotrigine achieved for a given dosing regimen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/12/20 alle ore 21:16:52